ArticleHealth services research2020
The unintended consequences of the 340B safety-net drug discount program.
Article in Health services research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Association of 340B entity eligibility with changes in hospital financial performance.Health affairs scholar · 2026Article
- Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study.BMC health services research · 2025Observational
- US Hospital Service Availability and New 340B Program Participation.JAMA health forum · 2024Article
- "Not what we signed up for": Nurse shortages, physician scarcity, and time for collective bargaining?World medical & health policy · 2024Article
- Outcomes of the 340B Drug Pricing Program: A Scoping Review.JAMA health forum · 2023Article
- Sources of Clinician Burnout in Providing Care for Underserved Patients in a Safety-Net Healthcare System.Journal of general internal medicine · 2023Article
- Community Health Center 340B Program: A Qualitative Study of the Experiences of Patients with Diabetes.Innovations in pharmacy · 2023Article
- Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.JAMA network open · 2022Article
- Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.Health affairs (Project Hope) · 2021Article
- The Association of 340B Program Drug Margins with Covered Entity Characteristics.Inquiry : a journal of medical care organization, provision and financingArticle
- Mapping 340B Funds Flow Through Contract Pharmacies.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.